High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling

被引:37
作者
Bastien, Roy [1 ]
Lewis, Tracey B. [2 ]
Hawkes, Jason E. [1 ]
Quackenbush, John F. [1 ]
Robbins, Thomas C. [3 ]
Palazzo, Juan [4 ]
Perou, Charles M. [5 ,6 ]
Bernard, Philip S. [1 ,2 ]
机构
[1] Univ Utah, Huntsman Canc Inst, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA
[2] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA
[3] Idaho Technol Inc, Salt Lake City, UT USA
[4] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Sci, Chapel Hill, NC 27599 USA
关键词
high-throughput; scanning; high-resolution melting; automatic calling; TP53;
D O I
10.1002/humu.20726
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Identifying mutations in the TP53 gene is important for cancer prognosis, predicting response to therapy, and determining genetic risk. We have developed a high-throughput scanning assay with automatic calling to detect TP53 mutations in DNA from fresh frozen (FF) and formalin,fixed paraffin-embedded (FFPE) tissues. The coding region of the TP53 gene (exons 2-11) was PCR amplified from breast cancer samples and scanned by high-resolution fluorescent melting curve analyses using a 384 well format in the LightCycler 480 instrument. Mutations were confirmed by direct sequencing. Sensitivity and specificity of scanning and automatic mutation calling was determined for FF tissue (whole genome amplified [WGA] and non WGA) and FFPE tissue. Thresholds for automatic mutation calling were established for each preparation type. Overall, we confirmed 27 TP53 mutations in 68 primary breast cancers analyzed by high,resolution melting curve scanning and direct sequencing. Using scanning and automatic Calling, there was high specificity (>95%) across all DNA preparation methods. Sensitivities ranged from 100% in non-WGA DNA from fresh tissue to 86% in WGA DNA and DNA from formalin-fixed, paraffin-embedded tissue. Scanning could detect mutated DNA at a dilution of 1:200 in a background of wild-type DNA. Mutation scanning by high-resolution fluorescent melting curve analyses can be done in a high-throughput and automated fashion. The TP53 scanning assay can be performed from a variety of specimen types with high sensitivity/specificity and could be used for clinical and research purposes.
引用
收藏
页码:757 / 764
页数:8
相关论文
共 49 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array [J].
Ahrendt, SA ;
Halachmi, S ;
Chow, JT ;
Wu, L ;
Halachmi, N ;
Yang, SC ;
Wehage, S ;
Jen, J ;
Sidransky, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7382-7387
[3]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[4]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
[5]  
Berns EMJJ, 2000, CANCER RES, V60, P2155
[6]   Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen [J].
Bertheau, Philippe ;
Turpin, Elisabeth ;
Rickman, David S. ;
Espie, Marc ;
de Reynies, Aurelien ;
Feugeas, Jean-Paul ;
Plassa, Louis-Francois ;
Soliman, Hany ;
Varna, Mariana ;
de Roquancourt, Anne ;
Lehmann-Che, Jacqueline ;
Beuzard, Yves ;
Marty, Michel ;
Misset, Jean-Louis ;
Janin, Anne ;
de The, Hugues .
PLOS MEDICINE, 2007, 4 (03) :585-594
[7]   CONSTANT DENATURANT GEL-ELECTROPHORESIS AS A RAPID SCREENING TECHNIQUE FOR P53 MUTATIONS [J].
BORRESEN, AL ;
HOVIG, E ;
SMITHSORENSEN, B ;
MALKIN, D ;
LYSTAD, S ;
ANDERSEN, TI ;
NESLAND, JM ;
ISSELBACHER, KJ ;
FRIEND, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8405-8409
[8]   TP53 and breast cancer [J].
Borresen-Dale, AL .
HUMAN MUTATION, 2003, 21 (03) :292-300
[9]   Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[10]   ACCUMULATION OF P53 PROTEIN AS A POSSIBLE PREDICTOR OF RESPONSE TO ADJUVANT COMBINATION CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, FLUOROURACIL, AND PREDNISONE FOR BREAST-CANCER [J].
ELLEDGE, RM ;
GRAY, R ;
MANSOUR, E ;
YU, YY ;
CLARK, GM ;
RAVDIN, P ;
OSBORNE, CK ;
GILCHRIST, K ;
DAVIDSON, NE ;
ROBERT, N ;
TORMEY, DC ;
ALLRED, DC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (16) :1254-1256